Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07225504 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Study acronym: REMASTER
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 256 → 296 locations
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 5 of 8 entries
  2. Trial sites expanded: 236 → 256 locationsv20
  3. Trial sites expanded: 223 → 236 locations
    • Eligibility criteria revised
    v19
  4. Trial sites expanded: 208 → 223 locationsv18
  5. Trial sites expanded: 200 → 208 locationsv17
  6. Trial sites expanded: 187 → 200 locationsv16
  7. Trial sites expanded: 180 → 187 locationsv15
  8. Trial sites expanded: 164 → 180 locationsv14
  9. Trial sites expanded: 136 → 164 locationsv13
  10. Trial sites expanded: 90 → 136 locationsv12
  11. Trial sites expanded: 61 → 90 locationsv11
  12. Trial sites expanded: 44 → 61 locationsv10
  13. Study sites: 37 to 44v9
  14. Study sites: 24 to 37v8
  15. Study sites: 17 to 24v7
  16. Study sites: 13 to 17v6
  17. Study sites: 12 to 13v5
  18. Study sites: 10 to 12v4
  19. Study sites: 7 to 10v3
  20. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 7
    • Start date changed from estimate of Dec 1, 2025 to Nov 11, 2025
    v2
  21. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
Multiple Sclerosis
1,011 trials monitored
See 34 trials at risk
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
Trial Details
NCT Number NCT07225504
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Secondary Progressive Multiple Sclerosis (SPMS)
Related terms Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Enrollment 1,275 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov